» Articles » PMID: 37162594

Predictors for Major In-hospital Complications After Catheter Ablation of Ventricular Arrhythmias: Validation and Modification of the Risk in Ventricular Ablation (RIVA) Score

Abstract

Objective And Background: Catheter-based treatment of patients with ventricular arrhythmias (VA) reduces VA and mortality in selected patients. With regard to potential risks of catheter ablation, a benefit-risk assessment should be carried out. This can be performed with risk scores such as the recently published "Risk in Ventricular Ablation (RIVA) Score". We sought to validate this score and to test for possible additional predictors in a large database of VT ablations.

Methods And Results: We analyzed 1964 catheter ablations for VA in patients with (1069; 54.4%) and without (893, 45.6%) structural heart disease (SHD) and observed an overall major adverse event rate of 4.0% with an in-hospital mortality of 1.3% with significantly less complications occurring in patients without structural heart disease (6.5% vs. 1.1%; p ≤ 0.01). The RIVA Score demonstrated to be a valid predictive tool for major in-hospital complications (OR 1.18; 95% CI 1.12, 1.25; p ≤ 0.001). NYHA Class ≥ III (OR 2.5; 95% CI 1.5, 4.2; p < 0.001) and age (OR 1.04; 95% CI 1.02, 1.07; p ≤ 0.001) proved to be additional predictive parameters. Hence, a modified RIVA Score (mRIVA) model was analyzed with a subset of established predictors (SHD, eGFR, epicardial puncture) as well as new predictive parameters (age, NYHA Class ≥ III), that achieved a higher predictive value for major complications compared with the model based on all RIVA variables.

Conclusion: Adding age and functional heart failure status (NYHA class) as simple clinical parameters to the recently published RIVA Score increases the predictive value for ablation-associated complications in a large VT ablations registry.

Citing Articles

Pre-ablation and Post-ablation Factors Influencing the Prognosis of Patients with Electrical Storm Treated by Radiofrequency Catheter Ablation: An Update.

Cojocaru C, Dorobantu M, Vatasescu R Rev Cardiovasc Med. 2025; 25(12):432.

PMID: 39742218 PMC: 11683710. DOI: 10.31083/j.rcm2512432.


MSA-VT Score for Assessment of Long-Term Prognosis after Electrical Storm Ablation.

Vatasescu R, Cojocaru C, Gondos V, Iorgulescu C, Bogdan S, Onciul S Biomedicines. 2024; 12(3).

PMID: 38540108 PMC: 10968369. DOI: 10.3390/biomedicines12030493.


Major in-hospital complications after catheter ablation of cardiac arrhythmias: individual case analysis of 43 031 procedures.

Eckardt L, Doldi F, Anwar O, Gessler N, Scherschel K, Kahle A Europace. 2023; 26(1).

PMID: 38102318 PMC: 10754182. DOI: 10.1093/europace/euad361.

References
1.
Della Bella P, Baratto F, Vergara P, Bertocchi P, Santamaria M, Notarstefano P . Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial. Circulation. 2022; 145(25):1829-1838. DOI: 10.1161/CIRCULATIONAHA.122.059598. View

2.
Willems S, Tilz R, Steven D, Kaab S, Wegscheider K, Geller L . Preventive or Deferred Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy and Implantable Defibrillator (BERLIN VT): A Multicenter Randomized Trial. Circulation. 2020; 141(13):1057-1067. DOI: 10.1161/CIRCULATIONAHA.119.043400. View

3.
Tung R, Xue Y, Chen M, Jiang C, Shatz D, Besser S . First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial. Circulation. 2022; 145(25):1839-1849. DOI: 10.1161/CIRCULATIONAHA.122.060039. View

4.
Arenal A, Avila P, Jimenez-Candil J, Tercedor L, Calvo D, Arribas F . Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia. J Am Coll Cardiol. 2022; 79(15):1441-1453. DOI: 10.1016/j.jacc.2022.01.050. View

5.
Hosseini S, Rozen G, Saleh A, Vaid J, Biton Y, Moazzami K . Catheter Ablation for Cardiac Arrhythmias: Utilization and In-Hospital Complications, 2000 to 2013. JACC Clin Electrophysiol. 2018; 3(11):1240-1248. DOI: 10.1016/j.jacep.2017.05.005. View